The International Federation of Gynecology and Obstetrics (FIGO) has proposed an updated staging system for endometrial cancer that incorporates histological and molecular features. This new system aims to address the heterogeneity of the disease and improve prognostication. However, there are concerns about the complexity of the new system and the lack of evidence supporting certain aspects, such as the role of molecular and genomic classification. The focus of the classification is not on describing the extent of the disease, and it may be more useful for identifying different risk categories. Further research is needed to validate and refine the new staging system. [Extracted from the article]